1. Home
  2. INZY

as 03-28-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.

Founded: 2015 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 64.9M IPO Year: 2020
Target Price: $16.90 AVG Volume (30 days): 516.9K
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.62 EPS Growth: N/A
52 Week Low/High: $0.91 - $7.80 Next Earning Date: 03-10-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

INZY Daily Stock ML Predictions

Share on Social Networks: